Menu

Cancer Treatment & Care

Fruits and vegetables with green joice

Well-Meaning, But Bad Advice For Cancer

Well-Meaning, But Bad Advice For Cancer

4 Common Cancer Myths Worth Rethinking

Well-Meaning, But Bad Advice For Cancer

4 Common Cancer Myths Worth Rethinking

When someone is diagnosed with cancer, advice pours in from every direction — family, friends, social media groups, well-intentioned strangers. Most of it comes from a good place. Some of it is even advice that used to be correct. But a few pieces of “common knowledge” turn out to work against you once you look at what the current evidence actually shows.

Here are four of the most common ones, and what to do instead.

1. “Eat whatever you want to gain weight before chemo”

The advice: Treatment might make it hard to eat, so pack on calories now as a buffer.

Why it’s outdated: Major oncology guidelines actually recommend the opposite. The American Society of Clinical Oncology’s guideline on diet and weight management during cancer treatment focuses on preventing weight gain, not encouraging it [1]. In breast, colon, and prostate cancer specifically, higher body fat and weight gain during treatment are linked to worse outcomes, not better tolerance of chemo [2][3].

Why it matters: Excess fat tissue isn’t inert — it’s metabolically active and drives chronic, low-grade inflammation, which feeds tumor growth (more on that below). What actually helps heading into treatment is preserving muscle mass and metabolic health, through adequate (but not too much!) protein, deep therapeutic nutrition and movement — not stacking on calories and sugar.

2. The bigger picture: how sugar and insulin feed cancer growth

This is the science behind why myth #1 — and the next two — matter.

Cancer cells run on glucose differently than healthy cells do. Even when oxygen is available, they preferentially ferment glucose for fuel, a phenomenon called the Warburg effect. Glucose and insulin spikes don’t just supply that fuel — insulin and related growth signaling can directly switch on the same cellular pathways tumors use to grow and spread.

Two researchers have spent their careers studying this:

Dr. Thomas Seyfried (Boston College) studies cancer as a metabolic disease and researches ketogenic metabolic therapy as a way to reduce the fuel — glucose and glutamine — that tumors depend on [4]. This is a genuinely active, still-evolving research area, considered an overlooked but important treatment avenue to leverage versus replacement for standard treatment.

Dr. Valter Longo (USC) has clinical trial data — including a randomized trial in breast cancer patients — showing that short fasting-mimicking diet cycles around chemotherapy improved treatment response and reduced fatigue, likely by protecting healthy cells while leaving cancer cells more vulnerable [5][6].

This same mechanism is also why we don’t recommend insulin potentiated therapy (IPT) — using injected insulin to drop blood sugar dramatically, then giving a much smaller dose of chemotherapy timed to that drop, on the theory that glucose-hungry cancer cells will preferentially take up the chemo and let you lower the overall toxic load. It’s an appealing idea, and it isn’t new — it dates back nearly a century — and initial results often look genuinely good: tumor shrinkage, far fewer side effects [7]. But insulin itself is a growth signal, switching on many of the same pathways described above, and in practice we tend to see a dramatic resurgence of the cancer within a short period of time afterward. Tellingly, the physicians who originally developed and popularized this low-dose IPT approach no longer use it themselves, having watched this same pattern play out [8].

The takeaway: lowering glucose and insulin load appears to work with treatment, not against it — but only when it doesn’t involve adding more insulin into the system. That’s why timing and method matter, and why the best time to start building a metabolic strategy is at diagnosis, with a properly trained practitioner, before chemo begins, not after.

3. Juicing

The advice: Juicing is a healthy way to load up on nutrients.

Why it’s outdated: In the late 1800s and early 1900s, juicing was genuinely useful — it concentrated nutrients from produce that was otherwise hard to eat in volume, in a food environment very different from today’s.

Two things have changed. First, even organic produce today can carry glyphosate residue, since it’s one of the most widely used herbicides in modern agriculture [9][10]. Juicing means drinking the extract of many servings of produce at once, so whatever residue is present is consumed in a concentrated dose rather than spread across whole servings and somewhat bound up in fiber. Second, and more directly supported by the evidence: juicing strips out the fiber that normally slows sugar absorption. The result is a fast, high-glycemic hit of fruit and vegetable sugar with none of the fiber that would blunt it — exactly the kind of glucose and insulin spike described above.

What helps instead: consume whole fruits and vegetables with the fiber intact, or blending (keeping the pulp) rather than juicing.

4. Getting repurposed drugs off social media, without medical oversight

The advice: Cancer support groups on Facebook and elsewhere often circulate “protocols” using repurposed drugs — ivermectin, fenbendazole, and others — as miracle treatments.

Why it’s dangerous: Fenbendazole is a veterinary dewormer. The FDA has never approved it for human use, in any form or dose. ASCO issued a clinical notice specifically recommending against using fenbendazole for cancer treatment outside of a formal clinical trial [11][12]. Documented harms include liver injury from self-administered fenbendazole, and the deeper danger is that nobody is monitoring for drug interactions, toxicity, or proper dosing alongside actual cancer treatment [13].

This isn’t hypothetical. About four years ago, I lost a patient who had obtained fenbendazole through a Facebook group with no medical oversight at all. That loss has stayed with me.

The flip side: Repurposed drugs and metabolic strategies can have a real, legitimate place in a treatment plan. The difference is doing it with a properly trained integrative or metabolic-oncology practitioner who monitors dosing, combinations, and timing alongside your oncology team — not a Facebook group.

The bottom line

A lot of “common knowledge” in cancer care was either never quite right or hasn’t caught up with what we now understand about metabolism, inflammation, and cancer growth. If you or someone you love is newly diagnosed, the best time to build a thoughtful, supervised metabolic strategy is now — before treatment starts, not scrambling afterward.

This is educational content, not medical advice. Always talk to your oncology team before changing your treatment, diet, or supplement plan.

References

1. Ligibel, J. et al. “Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.” Journal of Clinical Oncology (2022). ascopubs.org/doi/10.1200/JCO.22.00687

2. “Pre-to-post diagnosis weight trajectories in colorectal cancer patients with non-metastatic disease.” PMC. ncbi.nlm.nih.gov/pmc/articles/PMC6394719

3. “Is weight gain preventable in women with early breast cancer undergoing chemotherapy?” PMC. ncbi.nlm.nih.gov/pmc/articles/PMC10564810

4. Thomas N. Seyfried faculty profile, Boston College Biology Department. bc.edu/…/thomas-seyfried.html

5. “Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.” Nature Communications (2020). nature.com/articles/s41467-020-16138-3

6. “A Better Quality of Life and Less Fatigue: New Evidence of the Benefits of Fasting During Chemotherapy.” Fondazione Valter Longo. valterlongo.com/…fasting-during-chemotherapy

7. “Low-Dose Chemotherapy with Insulin (Insulin Potentiation Therapy) in Combination with Hormone Therapy for Treatment of Castration-Resistant Prostate Cancer.” PMC. pmc.ncbi.nlm.nih.gov/articles/PMC3357525

8. “Insulin Potentiation Therapy” overview — history, safety, and outcomes data. CAM-Cancer / CancerChoices. cam-cancer.org/insulin-potentiation-therapy and cancerchoices.org/therapy/insulin-potentiation-therapy

9. Vicini, J. et al. “Residues of glyphosate in food and dietary exposure.” Comprehensive Reviews in Food Science and Food Safety (2021). ift.onlinelibrary.wiley.com/doi/10.1111/1541-4337.12822

10. “Analysis of Glyphosate Residues in Foods from the Canadian Retail Markets between 2015 and 2017.” Journal of Agricultural and Food Chemistry. pubs.acs.org/doi/10.1021/acs.jafc.9b07819

11. American Cancer Society. “What to Know About Fenbendazole.” cancer.org/cancer/latest-news/what-to-know-about-fenbendazole.html

12. ASCO Clinical Notice: “Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials.” connection.asco.org/…fenbendazole-cancer-treatment

13. “Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole.” PMC. pmc.ncbi.nlm.nih.gov/articles/PMC11068125

lotus graphic with healing natural elements

Supporting the Body Through Biopsy and Cancer Surgery: An Integrative Approach to the Perioperative Window

0

Supporting the Body Through Biopsy & Cancer Surgery:

An Integrative Approach to the Perioperative Window

Supporting the Body Through Biopsy and Cancer Surgery:

An Integrative Approach to the Perioperative Window

Biopsy and surgery are among the most important tools we have in cancer care. A biopsy can provide the diagnosis and molecular information needed to choose appropriate treatment. Surgery can remove a primary tumor, reduce tumor burden, prevent complications, and, for many localized cancers, offer the possibility of cure.

The goal of integrative care is not to avoid medically necessary biopsy or surgery.

Instead, we ask another question:

Can we support the body’s physiology before and after a procedure in ways that promote healing, preserve immune function, and potentially make the perioperative environment less favorable to residual cancer cells?

There are compelling biological reasons to have that conversation.

Surgery Is More Than a Local Event

When tissue is injured, the body immediately launches a sophisticated wound-healing program. Stress hormones rise. Inflammatory pathways activate. Blood vessels and connective tissue begin remodeling. Growth factors are released. Immune activity changes.

These responses are essential—we could not heal without them.

But cancer biology can sometimes take advantage of the same signals.

Research on the perioperative period has shown that surgical stress can increase catecholamines, prostaglandins, inflammatory cytokines, vascular growth signals, and other mediators while temporarily suppressing aspects of antitumor immunity, including natural killer (NK) cell function.

Many of these pathways—including inflammatory signaling, angiogenesis, tissue remodeling, migration, and stem/progenitor-cell programs—also participate in tumor progression. This overlap is one reason cancer has historically been described as behaving in some ways like a “wound that does not heal.”

This does not mean we should avoid biopsy and surgery. For many cancers, surgery is lifesaving and remains the cornerstone of curative treatment.

It means that the days surrounding biopsy or surgery represent a biologically active window that deserves attention.

What About Biopsy?

Needle-tract seeding has been reported with certain tumors and procedures, but it is uncommon for most cancers, and human studies have not established that routine biopsy increases distant metastasis.

At the same time, a biopsy is still a tissue injury and produces a localized wound-healing response. For that reason, we believe it is reasonable to think about supporting healthy inflammatory regulation and tissue repair around a biopsy.

The Perioperative Stress Response and Cancer Biology

Cancer surgery creates several overlapping physiological responses.

Inflammation: Tissue injury activates inflammatory mediators necessary for wound repair. In the cancer setting, some of these same pathways can also influence angiogenesis, invasion, epithelial-to-mesenchymal transition (EMT), and survival of residual tumor cells.

Stress hormones: Surgery and the psychological stress surrounding a cancer diagnosis can increase sympathetic nervous system activity and catecholamines such as epinephrine and norepinephrine.

Prostaglandins: Surgical inflammation increases prostaglandin signaling, including pathways involving COX-2 and PGE2.

Temporary immune suppression: NK cells and cytotoxic T cells are important components of immune surveillance against malignant cells. Their function may decline temporarily following major surgery.

The biological objective is therefore not to eliminate inflammation—we need inflammation to heal—but to support an appropriate, well-regulated inflammatory response while preserving immune resilience.

An Intriguing Area of Research: Beta Blockers and Anti-Inflammatory Medications

One of the most interesting areas of perioperative oncology research involves simultaneously targeting the stress and inflammatory responses.

In a randomized phase II study of 38 women undergoing breast cancer surgery, patients received the beta blocker propranolol together with the COX-2–inhibiting anti-inflammatory medication etodolac, beginning five days before surgery and continuing through the perioperative period.

Compared with placebo, treated tumors showed favorable changes in several biomarkers associated with metastatic biology, including reductions in epithelial-to-mesenchymal transition and pro-inflammatory/pro-metastatic transcriptional activity.

Another randomized phase II trial studied propranolol alone for seven days before breast cancer surgery. Researchers observed reduced expression of mesenchymal and inflammatory programs—including changes involving NF-κB and AP-1—and changes suggesting greater immune-cell infiltration into the tumor.

These are fascinating findings, but there is an important distinction:

These trials demonstrated changes in biological markers. They have not yet established that perioperative beta blockers or anti-inflammatory medications reduce cancer recurrence or improve overall survival.

These medications also have real contraindications and risks. Beta blockers can affect heart rate, blood pressure, and airway function, while anti-inflammatory medications may affect bleeding, kidney function, gastrointestinal health, and surgical planning.

They should therefore only be considered in collaboration with the patient’s oncology, surgical, anesthesia, and prescribing teams.

Nutritional and Botanical Support

At Elevate Health, perioperative planning may also include nutritional and botanical compounds selected for their potential effects on inflammatory signaling, oxidative stress, tissue repair, and cancer-related pathways.

Depending upon the individual, compounds we may consider include:

  • Boswellia: approximately 1,000 mg twice daily
  • Curcumin phytosome: 500–1,000 mg twice daily
  • Quercetin: up to 1,000 mg twice daily
  • Grape seed extract: 250–500 mg once to twice daily
  • Berberine: 500 mg twice daily with meals
  • Black seed/thymoquinone: dosing individualized to the product; in some protocols approximately 200 mg twice daily

These doses are examples from our clinical protocols, not universal recommendations.

Evidence for these compounds ranges from mechanistic and preclinical research to limited human data; they should not be represented as proven methods of preventing perioperative cancer spread or recurrence.

Just as importantly, “natural” does not mean appropriate immediately before surgery. Supplements can affect platelet function, glucose, blood pressure, drug metabolism, anesthesia, or other aspects of perioperative care. Your surgeon and anesthesiologist should have a complete list of everything you take, and their instructions about what to stop before surgery take priority.

Modified Citrus Pectin and Galectin-3

Another compound we consider is modified citrus pectin (MCP).

MCP has been studied as an antagonist of galectin-3, a carbohydrate-binding protein involved in cellular adhesion, inflammation, fibrosis, angiogenesis, and several aspects of cancer biology.

Preclinical studies demonstrate effects of MCP on galectin-3–related tumor adhesion, angiogenesis, invasion, and growth. Human research remains preliminary, although a phase II study in men with biochemically recurrent prostate cancer found potentially favorable changes in PSA kinetics during MCP treatment.

Our clinical protocol commonly uses:

Modified citrus pectin: 15 grams daily, beginning approximately two weeks before biopsy or surgery and continuing for at least one month afterward.

In patients with confirmed cancer, we may also follow galectin-3 and individualize continued MCP use, with a clinical target of less than 10 ng/mL.

It is important to emphasize that using a galectin-3 target of <10 in this setting is an integrative clinical strategy rather than an established oncology guideline, and evidence has not established that MCP around surgery prevents metastasis or recurrence.

For benign biopsy findings, we generally do not continue cancer-directed MCP monitoring solely for this purpose.

Our Basic Pre- and Post-Biopsy/Surgical Support Protocol

Every patient is different, and surgical instructions always take priority. Depending on the procedure, medical history, medications, laboratory findings, and cancer type, our foundational protocol may include the following.

Vitamin C

1,000 mg two to three times daily for at least two weeks after surgery.

Vitamin C plays an important role in collagen synthesis and connective-tissue repair and supports antioxidant defenses during recovery.

Modified Citrus Pectin

15 grams daily, generally beginning two weeks before the procedure and continuing for at least one month afterward.

In selected cancer patients, galectin-3 may be monitored to help individualize longer-term use.

Zinc

25 mg twice daily or 50mg once daily with food, generally for two weeks before and two weeks after surgery.

Zinc is essential for immune function, protein synthesis, and wound healing. Higher-dose zinc should generally be used for limited periods unless zinc and copper status are being monitored.

Vitamin A

Our protocol may use 20,000 IU daily of emulsified vitamin A for approximately two weeks before and two weeks after surgery, when appropriate.

Vitamin A participates in epithelial integrity, immune function, and wound healing. This dose is not appropriate for everyone—particularly during pregnancy or when liver disease, retinoid medications, or other contraindications are present.

Probiotic Support

A mixed probiotic may be started approximately two weeks before surgery and continued for at least two weeks afterward, or continued longer when otherwise indicated.

One example used in our practice is RestorFlora, one capsule in the evening.

Fish Oil

We commonly have patients discontinue supplemental fish oil approximately 72 hours before major surgery, unless the surgical team advises otherwise.

This is generally not necessary for a routine fine-needle biopsy.

Restart timing should be confirmed with the surgeon, particularly when anticoagulants or antiplatelet medications are being used.

After Surgery: Supporting Recovery

Once the procedure is complete and the surgeon has confirmed that bleeding risk is controlled, our attention shifts toward recovery, mobility, connective-tissue repair, bowel function, pain management, and restoration of normal physiology.

Proteolytic Enzymes

Selected patients may use systemic proteolytic enzyme formulas such as Wobenzym or similar products, often taken away from food.

Because some enzyme products can affect bleeding or interact with medications, they should not be started immediately after surgery without clearance from the surgical team.

Gentle Lymphatic and Recovery Support

Depending on the surgery and stage of healing, supportive strategies can include:

  • Gentle walking and progressive movement
  • Hydration and adequate protein intake
  • Constipation prevention
  • Breathing exercises
  • Gentle lymphatic support when appropriate
  • Acupuncture for postoperative pain, nausea, and recovery
  • Castor oil packs later in recovery when appropriate and never over a fresh incision
  • Sauna only after adequate healing, hydration, and medical clearance

Rather than thinking of these interventions as “detoxing anesthesia,” we prefer to think about them as supporting circulation, bowel function, mobility, lymphatic flow, relaxation, and recovery while the liver and kidneys perform the body’s normal clearance processes.

What About IV Vitamin C?

For appropriate patients, we may consider intravenous vitamin C as part of an individualized postoperative oncology plan.

Our clinical protocol may include 25–50 grams of IV vitamin C within approximately 48 hours after surgery, once the patient is medically stable, followed by several treatments during the subsequent two weeks.

IV vitamin C has pharmacologic properties very different from oral vitamin C and is being actively investigated in oncology.

High-dose IV vitamin C also requires appropriate screening and medical supervision, including consideration of G6PD status, kidney function, hydration, iron overload disorders, and medication/treatment interactions. Timing must be coordinated with the oncology and surgical teams.

Homeopathic Support

Some patients in our practice also choose homeopathic preparations around major surgery, including Arnica, Staphysagria, Phosphorus, and Hypericum. These are optional complementary therapies which have long term historical use in healing and recovery and are well regarded as safe.  

The Bigger Picture: Don’t Fear the Procedure—Prepare for It

A cancer diagnosis can make every decision feel loaded with risk. 

Biopsies provide information that can be essential for choosing the right treatment. Surgery cures or controls many cancers. We should not delay a medically necessary procedure out of fear of the body’s wound-healing response.

At the same time, modern tumor biology gives us an increasingly sophisticated understanding of the perioperative period.

Surgery is not merely an event that happens to a tumor. It is an event experienced by the whole person—their nervous system, immune system, inflammatory pathways, metabolism, vasculature, and healing tissues.

That creates an opportunity.

Before a biopsy or surgery, we can ask:

How can we improve nutritional status?

How can we support wound healing?

How can we maintain muscle and metabolic health?

Can we improve sleep and reduce excessive sympathetic stress?

Are there deficiencies that should be corrected?

Which supplements should be stopped for surgical safety?

And, for patients with cancer, are there evidence-informed strategies worth discussing with the medical team to support the unique biology of the perioperative window?

This is what integrative oncology can do well: not replace necessary cancer treatment, but prepare the terrain around it.

The goal is to help patients enter surgery as physiologically resilient as possible—and come out with the support they need to heal, recover, and move confidently into the next phase of treatment.

Important Safety Note

This article is educational and is not a universal pre- or postoperative prescription. Supplements and medications can interact with anesthesia, anticoagulants, chemotherapy, targeted therapies, immunotherapy, blood-pressure medications, diabetes medications, and other treatments. Some supplements may need to be stopped considerably earlier than 72 hours before surgery.

Always provide your surgeon, anesthesiologist, oncologist, and integrative clinician with a complete medication and supplement list before a procedure. Do not start or stop prescription medications—including beta blockers or anti-inflammatory medications—without the prescribing and surgical teams.

References

Hiller JG, et al. Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. Clinical Cancer Research. 2020.

Shaashua L, et al. Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Clinical Cancer Research. 2017.

Angka L, et al. Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery. International Journal of Molecular Sciences. 2017.

Ben-Eliyahu S. et al. Research examining catecholamines, prostaglandins, perioperative immune suppression, and metastatic biology.

Keizman D, et al. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 2021.

Jiang J, et al. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds in the suppression of invasive behavior of human breast and prostate cancer cells. Integrative Cancer Therapies. 2013.

Shakhar G, Ben-Eliyahu S, and subsequent investigators. Reviews of perioperative stress, immune function, and metastatic mechanisms.

Asian woman hand on chin thinking

Can Psilocybin Repair Nerve Damage from Chemotherapy?

0

Can Psilocybin Repair Nerve Damage from Chemotherapy?

Can Psilocybin Repair Nerve Damage from Chemotherapy?

Here’s What the Research Actually Shows

Chemotherapy-induced peripheral neuropathy, or CIPN, is one of the most common and stubborn side effects of cancer treatment. It affects up to 70% of patients who receive neurotoxic drugs like taxanes and platinum-based chemotherapies, producing tingling, numbness, burning pain, and muscle weakness in the hands and feet. For many survivors, it lingers for years after treatment ends, and there is still no approved drug that reliably prevents or reverses it.

That gap is why a new psilocybin trial at MD Anderson Cancer Center has drawn attention. But it’s worth being precise about what this research is actually testing, because the popular framing of “psilocybin repairs nerve damage” runs ahead of the evidence. Here’s what’s real, what’s hypothesized, and what’s still unknown.

The MD Anderson trial: NeuroGuard

The study in question is a Phase 2 trial called NeuroGuard (ClinicalTrials.gov identifier NCT07227909), sponsored by MD Anderson Cancer Center with the Usona Institute as a collaborator, and led by principal investigator Dr. Moran Amit. It is designed to test whether psilocybin can prevent or reduce the severity of CIPN in patients about to start neurotoxic chemotherapy for breast, colorectal, or head and neck cancer.

The trial has three arms. In Arm A, participants receive two supervised oral doses of psilocybin a week apart before their first chemotherapy cycle, followed by two more supervised doses before cycles two and three. Arm B tests a “subperceptual” microdosing regimen, with low 1 mg doses taken every other day for two weeks before chemotherapy starts. Arm C is standard of care with no study drug, serving as the comparison group. The primary outcome is the proportion of participants whose CIPN symptoms worsen by 12 weeks, measured using the EORTC QLQ-CIPN20 sensory subscale, a validated patient-reported symptom questionnaire.

Two things are important to flag. First, this trial is aimed at prevention and symptom mitigation, not at reversing or “repairing” nerves that are already damaged. Second, as of this writing the trial has not yet reported results. It is a prospective study designed to generate evidence, not a completed study that has already shown psilocybin works for this purpose.

Why researchers think psilocybin might help

The rationale behind NeuroGuard draws on a few separate lines of research, none of which directly show peripheral nerve regeneration in humans, but which together make a plausible case for testing it.

The first line is preclinical work on psilocybin and pain. A 2025 study in Nature Neuroscience found that a single dose of psilocybin produced a rapid and long-lasting reduction in pain-like behavior in mice with nerve injury and inflammatory pain, an effect the researchers linked to activity in specific brain circuits rather than to any local effect at the injured nerve itself. A related study in the British Journal of Pharmacology reported similar findings: a single psilocybin dose led to prolonged reductions in pain behavior in a mouse model of neuropathy. Other preclinical work, summarized in an IUPHAR-affiliated review, ties these effects to activation of the serotonin 5-HT2A receptor, the same receptor responsible for psilocybin’s psychoactive effects. Penn Medicine’s research communications team summarized this body of work as psilocybin “targeting brain circuits” involved in pain processing, which is a meaningfully different mechanism than repairing damaged axons or myelin.

The second line is broader neuroplasticity research. A widely cited 2018 paper by David Olson and colleagues coined the term “psychoplastogen” to describe how psychedelics like psilocybin promote dendritic growth and new synaptic connections, initially observed in rodent cortical neurons. More recent work, including a 2025 eLife study using human iPSC-derived cortical neurons, extends this to human brain cells in a dish. This research supports the idea that psilocybin can promote structural plasticity in the central nervous system. It does not show that psilocybin regenerates injured peripheral sensory nerves in the hands and feet, which is a distinct biological process governed by different cell types (Schwann cells, dorsal root ganglion neurons) than the cortical plasticity these studies examine.

The third line is early clinical signal in adjacent conditions. A systematic review published in Regional Anesthesia & Pain Medicine found that across the studies it examined, 57% showed statistically significant reductions in chronic neuropathic pain symptoms after psilocybin therapy, though the review covered a small and heterogeneous set of studies. A separate trial has examined psilocybin-assisted therapy in patients with advanced cancer, finding improvements in quality of life, pain control, and anxiety, though this population was not selected for CIPN specifically. A preference-assessment study called PEACE-PAIN has also been conducted to gauge patient interest in psilocybin for chronic neuropathic pain ahead of a planned efficacy trial.

What this research does not show

It’s worth being explicit about the gap between the headlines and the data. No published human study has demonstrated that psilocybin repairs structural damage to peripheral nerves, such as regenerating axons or restoring myelin, in people with CIPN or any other form of peripheral neuropathy. The strongest mechanistic evidence so far points to central nervous system effects: altered pain processing in the brain and increased plasticity in cortical neurons. Whether those central effects translate into meaningful, durable relief of CIPN symptoms, let alone actual nerve repair, is precisely the question NeuroGuard and similar trials are designed to answer. It hasn’t been answered yet.

There’s also a regulatory backdrop worth noting. In early 2025, the FDA released draft guidance specifically addressing prevention and treatment of CIPN in drug development, reflecting how difficult this condition has been to target: symptoms are subjective and hard to standardize, the underlying biology involves multiple overlapping injury mechanisms, and because CIPN is a quality-of-life issue rather than immediately life-threatening, drug developers have historically been cautious about adding new agents that could interact with chemotherapy regimens.

The bottom line

MD Anderson’s NeuroGuard trial is a legitimate, actively-designed Phase 2 study testing whether psilocybin, given around the time of chemotherapy, can prevent or reduce CIPN symptoms. It’s grounded in real preclinical findings about psilocybin’s effects on pain circuits and neural plasticity. But it is testing a hypothesis, not confirming one, and the underlying science so far describes changes in brain pain processing and cortical plasticity, not regeneration of damaged peripheral nerves. Anyone encountering claims that psilocybin has been “shown” to repair chemo-induced nerve damage should treat that as a significant overstatement of where the evidence currently stands. The honest version of the story is that this is a promising, well-motivated line of inquiry with results still to come.

References

  1. NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy. ClinicalTrials.gov, Study NCT07227909. https://clinicaltrials.gov/study/NCT07227909
  2. Psilocybin for Neuropathy — Phase 2 Clinical Trial overview (MD Anderson Cancer Center, PI Moran Amit, MD). Power. https://www.withpower.com/trial/phase-2-psilocybin-4-2026-40959
  3. Single-dose psilocybin rapidly and sustainably relieves chronic pain-like behavior via brain circuit effects. Nature Neuroscience (2025). https://www.nature.com/articles/s41593-025-02068-0
  4. Askey, T. et al. Psilocybin as a novel treatment for chronic pain. British Journal of Pharmacology. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17420
  5. Psilocybin induces long-lasting effects via 5-HT2A receptor activation in mouse models of pain. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12107474/
  6. Psilocybin targets brain circuits to relieve pain. Penn Medicine News. https://www.pennmedicine.org/news/psilocybin-targets-brain-circuits-to-relieve-pain
  7. Olson, D. E. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. ACS Pharmacology & Translational Science (2018), reviewed via SAGE Journals. https://journals.sagepub.com/doi/10.1177/1179069518800508
  8. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. eLife (2025). https://elifesciences.org/articles/104006
  9. Investigating the therapeutic efficacy of psilocybin in advanced cancer. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271737/
  10. Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552286/
  11. Psilocybin and chronic neuropathic pain: a systematic review. Regional Anesthesia & Pain Medicine. https://rapm.bmj.com/content/50/11/845
  12. Chemotherapy induced peripheral neuropathy research is on the rise. The Foundation for Peripheral Neuropathy (Oct. 2025). https://www.foundationforpn.org/chemotherapy-induced-peripheral-neuropathy-research-is-on-the-rise/
  13. FDA draft guidance: Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy — Developing Drug and Biological Products (2025). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prevention-and-treatment-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological
Stethoscope and calendar

Why We Recheck Labs Every 4-6 Weeks for Our Cancer Patients

0

Why We Recheck Labs Every 4-6 Weeks
for Our Cancer Patients

Why We Recheck Labs Every 4-6 Weeks for Our Cancer Patients

If you’re being actively followed by our clinic for a cancer diagnosis, you’ve probably noticed a pattern: we don’t just run labs once and call it done. Patients sometimes ask why we test so often, especially when they’re feeling well. Here’s the honest answer: a single lab draw is a snapshot. What we’re really after is the movie.

A snapshot only tells you so much

One set of labs tells us where things stand today. But the body is not static — it’s responding, in real time, to infections, stress, sleep, inflammation, treatment, food, and everything in between. A single “normal” or “abnormal” result can’t tell us whether something is a blip or a trend. Only a series of labs, drawn consistently under the same conditions, can do that.

That’s why we ask you to fast 12-16 hours, be well hydrated, skip the coffee and tea, and try to test at the same time of day and month each time. Consistency in how the labs are drawn is what makes the trend line trustworthy.

Two cadences, individualized to you

This kind of frequent monitoring is specific to our cancer patients — it isn’t a one-size-fits-all schedule, and it isn’t how we approach every patient in our practice.

A core panel — CBC with differential, CMP, hsCRP, LDH, and sedimentation rate (ESR) — is rechecked every 4-6 weeks. These five give us the fastest-moving read on immune status, organ function, and inflammation, which is exactly why they’re worth checking often.

Everything else — methylation and nutrient markers, thyroid studies, iron storage, angiogenesis markers, and cancer-specific markers — is generally tracked every 1-3 months. The exact frequency is individualized to your case, your treatment plan, and what we’re watching most closely for you.

What these labs are actually telling us

Each of these labs is a window into a different system that can be stressed long before you feel it:

Metabolic function — glucose, fasting insulin, HgA1c, and the comprehensive metabolic panel (kidney and liver markers, electrolytes, protein and albumin) tell us how your body is handling fuel, hydration, and organ workload. Rising glucose or insulin, for example, can flag dysglycemia or stress on the endocrine system well before it becomes a bigger problem.

Immune status and cell counts — your CBC with differential (white cells, red cells, platelets, and the ratios between them) is one of the most sensitive windows we have into immune function and bone marrow activity. A dropping white count, a shifting neutrophil-to-lymphocyte ratio, or rising platelets can all point to something worth investigating — whether that’s a lingering viral infection, an inflammatory flare, or something that needs closer attention.

Inflammation markers — LDH, hsCRP, and sedimentation rate (what we sometimes call “the trifecta”) give us a read on inflammation and mitochondrial stress throughout the body. Individually, each can be nonspecific. Together, and tracked over time, they become far more meaningful.

Methylation and nutrient status — markers like homocysteine, MCV/MCH/MCHC, and vitamin D help us see how well your body is processing B vitamins, folate, and detoxification pathways. Methylation issues rarely show up as a single dramatic number; they show up as a slow drift that only becomes obvious when you’re looking at several data points in a row.

No single one of these labs is a verdict. Together, and repeated on a consistent cadence, they become a much clearer picture of what’s actually stressing your body — so we can address it proactively, rather than waiting for it to become symptomatic.

Why the trend matters more than any one result

This is the piece that’s easy to underestimate: the same result can mean very different things depending on what came before and after it, and catching a shift early is what allows us to actually do something about it.

We’ve seen this play out in our own patients. In one case, a patient being followed on this kind of frequent cadence had several key moments during treatment flagged by his labs — moments that, had they gone unchecked and unaddressed, could have shifted his terrain toward one more amenable to cancer progression. Because we were watching on a 4-6 week cycle rather than waiting months between draws, we caught those shifts early enough to act on them, rather than discovering them only after the fact.

That’s the real value of testing this often instead of only when something feels wrong. It’s not just about telling noise from signal — it’s about having enough lead time to actually change course. Over the long run, that difference in cadence can be the difference in outcome.

The bottom line

Frequent, consistent lab testing isn’t about chasing numbers. It’s about giving us — and you — the clearest possible view of your body’s terrain over time, so we can catch what’s stressing it early, tell the difference between noise and signal, and adjust your care proactively rather than reactively.

If you have questions about your own lab schedule or what a particular result might mean for you, please bring them to your next visit — this article is general education and isn’t a substitute for a conversation with your care team about your specific results.

health foos with drawing of a stomach

The Gut Microbiome and Cancer Care: Why It Matters More Than Ever

0

The Gut Microbiome and Cancer Care:
Why It Matters More Than Ever

The Gut Microbiome and Cancer Care: Why It Matters More Than Ever

In recent years, one of the most important—and often overlooked—factors influencing cancer outcomes has come into sharper focus: the health of the gut microbiome.

The trillions of bacteria, fungi, and microbes living in the gastrointestinal tract are not passive bystanders. They actively regulate immune function, inflammation, detoxification, and even how the body responds to cancer therapies. Emerging research continues to show a clear pattern: patients with a disrupted or imbalanced microbiome often experience poorer responses to treatment, including immunotherapy, chemotherapy, and targeted therapies.

The Microbiome–Immune System Connection

Roughly 70–80% of the immune system resides in the gut. This means the microbiome plays a central role in:

  • Training immune cells to recognize threats
  • Regulating inflammation
  • Supporting mucosal barrier integrity
  • Influencing T-cell activation and response

Immunotherapies—such as checkpoint inhibitors—depend on a well-functioning immune system to be effective. When the microbiome is compromised (a state known as dysbiosis), immune signaling becomes impaired.

The result? Reduced treatment efficacy.

Studies have shown that patients with greater microbial diversity and specific beneficial bacterial strains respond significantly better to immunotherapy compared to those with low diversity or pathogenic overgrowth.

Dysbiosis: A Hidden Barrier to Treatment Success

Several common factors contribute to an unhealthy microbiome in cancer patients:

  • Prior or repeated antibiotic use
  • Chemotherapy and radiation damage to the gut lining
  • Diets low in fiber and high in processed foods
  • Exposure to environmental toxins (such as glyphosate)
  • Chronic stress and poor sleep

Dysbiosis can lead to:

  • Increased intestinal permeability (“leaky gut”)
  • Chronic systemic inflammation
  • Impaired nutrient absorption
  • Altered drug metabolism

All of these can negatively influence treatment tolerance and outcomes.

Functional Testing: A Personalized Approach

To truly optimize the microbiome, testing is essential. Two of the most valuable tools in functional and integrative oncology include:

1. Comprehensive 3-Day Stool Analysis

This test evaluates:

  • Microbial diversity and balance
  • Presence of pathogenic bacteria, parasites, or yeast
  • Short-chain fatty acid production (like butyrate)
  • Inflammatory markers
  • Digestive function

It provides a detailed roadmap for targeted interventions.

2. 2-Hour SIBO Breath Test

Small Intestinal Bacterial Overgrowth (SIBO) is common in chronically ill patients and can significantly impair digestion and nutrient absorption.

This test measures hydrogen and methane gas production after consuming a substrate, helping identify bacterial overgrowth in the small intestine.

Why it matters:
Untreated SIBO can perpetuate inflammation and undermine nutritional and therapeutic strategies.

Foundational Strategies for a Healthy Microbiome

While targeted therapies and supplements can be helpful, the foundation of gut health always begins with daily inputs.

1. A High-Fiber, Polyphenol-Rich Diet

Fiber feeds beneficial bacteria and supports the production of short-chain fatty acids, which are critical for gut lining integrity and immune regulation.

Focus on:

  • Leafy greens and cruciferous vegetables
  • Flaxseeds, chia seeds, and psyllium fiber (as tolerated)
  • Low-glycemic dark berries
  • Herbs and spices rich in polyphenols (turmeric, rosemary, oregano)

Polyphenols act as prebiotics and help promote microbial diversity.

2. Avoiding Glyphosate and Conventional Foods

Glyphosate, a widely used herbicide, has been shown to disrupt the microbiome by selectively harming beneficial bacteria.

Whenever possible:

  • Choose organic produce
  • Avoid heavily sprayed grains and processed foods
  • Be mindful of environmental toxin exposure

Reducing toxic burden allows the microbiome—and immune system—to function more effectively.

3. Clean, Filtered Water

Water quality is often overlooked but critically important.

Chlorine, heavy metals, and other contaminants can negatively impact gut flora. A high-quality filtration system helps reduce this burden and supports overall cellular health.

Advanced Considerations: Fecal Microbiota Transplantation (FMT)

For certain patients—particularly those with severe dysbiosis or poor response to immunotherapy—fecal microbiota transplantation (FMT) is emerging as a powerful intervention.

FMT involves transferring beneficial microbes from a healthy donor into the patient’s gut to restore microbial balance.

Early research suggests that FMT may:

  • Enhance response to immunotherapy
  • Improve microbial diversity
  • Reduce inflammation

While not appropriate for every patient, it represents an exciting frontier in integrative cancer care and should be considered on a case-by-case basis under expert guidance.

The Takeaway

Cancer treatment is no longer just about targeting tumors—it’s about optimizing the terrain in which those tumors exist.

A healthy gut microbiome is foundational to:

  • Effective immune response
  • Improved treatment tolerance
  • Better overall outcomes

Without addressing the microbiome, even the most advanced therapies may fall short of their potential.

Final Thoughts

Supporting gut health is not a side strategy—it is a core pillar of comprehensive cancer care.

Through:

  • Functional testing
  • Strategic nutrition
  • Environmental detoxification
  • Personalized interventions

we can create an internal environment where therapies work with the body, not against it.

If you or a loved one are navigating cancer treatment, evaluating and optimizing the gut microbiome may be one of the most impactful steps you can take.

The One Thing All Cancer Cells Have in Common — and Why It Matters water ripple

The One Thing All Cancer Cells Have in Common — and Why It Matters

0

The One Thing All Cancer Cells Have in Common — and Why It Matters

The One Thing All Cancer Cells Have in Common — and Why It Matters

Cancer is often described as hundreds of different diseases, each with its own mutations, behaviors, and treatment challenges. Yet beneath this complexity, research continues to reveal a powerful unifying feature shared by virtually all cancer cells: damage to the mitochondria that disrupts normal energy production.

Understanding this common thread helps explain why cancer grows, how it survives, and why metabolic strategies—especially dietary changes—can meaningfully support better outcomes.

Mitochondria and the Loss of Normal Energy Production

Mitochondria are often called the “power plants” of the cell. In healthy cells, they produce energy through a highly efficient process known as oxidative phosphorylation (OXPHOS). This process occurs along the cristae, the folded inner membranes of the mitochondria that dramatically increase surface area for energy generation.

In cancer cells, these cristae are consistently found to be damaged, distorted, or flattened. When the cristae are disrupted, oxidative phosphorylation breaks down. The cell can no longer generate energy efficiently using oxygen, fats, and normal metabolic pathways.

This structural mitochondrial damage is now recognized as a foundational feature of cancer biology.

The Shift to Fermentation: A Hallmark of Cancer Metabolism

When oxidative phosphorylation fails, cells must adapt or die. Cancer cells adapt by reverting to a far more primitive energy strategy: fermentation.

Instead of producing energy in the mitochondria, cancer cells:

  • Rely heavily on glucose
  • Convert glucose into lactate, even when oxygen is present
  • Produce far less energy per unit of fuel

This phenomenon, known as the Warburg Effect, is seen across nearly all cancer types and is a direct consequence of mitochondrial dysfunction—not simply a preference or choice made by cancer cells.

Fermentation allows cancer cells to survive, but it also creates metabolic weaknesses that can be therapeutically targeted.

Cancer as a Metabolic Disease, Not Just a Genetic One

For decades, cancer has been described primarily as a genetic disease. However, accumulating evidence suggests a different sequence of events: mitochondrial damage comes first, and genetic changes follow.

When mitochondria fail, the nucleus receives distress signals and adapts by altering gene expression to support survival under low-energy conditions. Over time, this adaptive signaling can lead to the genetic mutations commonly observed in cancer cells.

This model helps explain several important findings:

  • Some cancers show no identifiable driver mutations
  • So-called “oncogenic” mutations are sometimes found in healthy or non-cancerous tissue
  • Genetic mutations alone are often insufficient to cause cancer without underlying metabolic dysfunction

Seen through this lens, cancer is best understood as a metabolic disease with genetic consequences, rather than a purely genetic disorder.

Why Diet and Metabolism Matter in Cancer Care

Because cancer cells are metabolically inflexible, their reliance on glucose and fermentation becomes a vulnerability.

Healthy cells—with intact mitochondria—can:

  • Use fats and ketones efficiently
  • Adapt to changes in fuel availability
  • Restore oxidative phosphorylation when supported

Cancer cells cannot.

This creates a powerful opportunity for dietary metabolic strategies that reduce fermentable fuels while supporting mitochondrial health.

Therapeutic dietary approaches—such as carbohydrate restriction, ketogenic metabolic therapy, and mitochondria-supportive nutrition—may help:

  • Lower circulating glucose and insulin
  • Reduce lactate production and tumor acidity
  • Decrease growth-promoting signaling pathways
  • Improve energy production and resilience in healthy tissues

Importantly, these strategies are not about deprivation or starvation. They are about selectively shifting the metabolic environment in ways that stress cancer cells while nourishing normal cells.

Supporting Better Outcomes Through Metabolic Strategy

Dietary metabolic support is not a replacement for conventional cancer treatments. Instead, it can work alongside standard care to:

  • Improve treatment tolerance
  • Reduce inflammation and fatigue
  • Support immune and mitochondrial function
  • Enhance quality of life and metabolic resilience

By targeting the one feature nearly all cancer cells share—damaged mitochondrial energy production—we gain a biologically grounded, non-toxic way to support the body during cancer care.

Metabolism matters. And for many patients, addressing it may be one of the most empowering steps in their healing journey.

Key Scientific References

  1. Warburg O. On the origin of cancer cells. Science. 1956.
  2. Seyfried TN. Cancer as a Metabolic Disease. Wiley, 2012.
  3. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012.
  4. Martínez-Outschoorn UE et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017.
  5. Baker SG, Kramer BS. Paradoxes in carcinogenesis. J Natl Cancer Inst. 2007.
A New Era in Cancer Care: Hope Beyond Chemotherapy - Cells

A New Era in Cancer Care: Hope Beyond Chemotherapy

0

A New Era in Cancer Care: Hope Beyond Chemotherapy

A New Era in Cancer Care: Hope Beyond Chemotherapy

Discover promising alternatives to chemotherapy like intratumoral MBTA and SYNC-T therapies. Learn how integrative, terrain-focused approaches can activate the immune system, protect healthy tissues, and support long-term healing.

We Are Overdue for Better Treatment Options

For decades, chemotherapy has been the default path after a cancer diagnosis. The idea was simple: kill cancer cells fast, reduce tumor size, and hope for remission. But as decades of research accumulate, the results tell a more complicated story.

While chemotherapy can temporarily shrink tumors, it also damages healthy tissues, weakens immunity, and—paradoxically— makes it easier for cancer to spread or return. Scientists now understand that the very treatment designed to stop cancer sometimes promotes long-term metastasis and resistance.

This realization has sparked a wave of innovation focused on smarter, more targeted, and less toxic therapies. Among the most exciting are intratumoral immunotherapies like MBTA and SYNC-T, which train your body’s own immune system to fight cancer, without widespread harm.

Why Systemic Chemotherapy Can Work Against the Body

Systemic chemotherapy circulates throughout the body, targeting all rapidly dividing cells. Unfortunately, it doesn’t discriminate between cancer cells and the healthy cells that line your gut, grow your hair, or form your immune defense.

Even more concerning, research now shows several mechanisms through which chemo  encourages cancer’s return or spread:

  • Stem cell activation: Chemotherapy can enrich cancer stem cells, highly resilient cells that can seed new tumors later.
  • Epithelial-to-mesenchymal transition (EMT): This biological shift allows cancer cells to loosen, migrate, and invade distant tissues.
  • Microenvironment disruption: Systemic chemo can inflame or damage tissue, preparing distant “soil” where cancer cells can take root.
  • Immune suppression: The body’s natural cancer-fighting defenses weaken during and after chemo, giving surviving tumor cells an advantage.

This doesn’t mean chemotherapy has no place in cancer treatment, but it highlights the urgent need for alternatives that heal and strengthen rather than harm and suppress.

A Smarter, More Localized Approach: Intratumoral Immunotherapy

Imagine if your tumor could become its own vaccine, training your immune system to recognize and destroy cancer cells throughout the body. That’s the vision behind intratumoral immunotherapy.

Instead of delivering toxic drugs through the bloodstream, these therapies are injected directly into the tumor. The treatment causes local cell death and inflammation that expose tumor antigens, unique molecular “fingerprints” of the cancer, to your immune system. The body learns to recognize these as foreign and mounts a systemic immune attack.

Two leading examples are:

MBTA Therapy

MBTA stands for Mannan-BAM + TLR ligands + anti-CD40 antibody. This combination stimulates multiple immune pathways to awaken both the innate and adaptive immune systems. Early studies show that MBTA can shrink local tumors and even trigger responses in distant, untreated sites, demonstrating a true “in situ vaccine” effect.

SYNC-T Therapy

The SYNC-T platform takes a personalized approach. Doctors partially freeze or ablate part of the tumor (to release its antigens) and then infuse a biologic mixture containing immune stimulants, like checkpoint inhibitors and CD40 agonists, directly into the tumor. Early results from the SYNC-T trial in patients with advanced prostate cancer showed strong immune responses and even resolution of metastases in some participants, all without the severe systemic side effects seen with standard chemo.

These therapies offer something truly hopeful: a way to activate the immune system while preserving quality of life.

Healing the Terrain: The Integrative Advantage

While intratumoral therapies focus on the tumor itself, the terrain of your body, your immune system, metabolism, mitochondria, and inflammation levels, plays a major role in whether cancer grows or retreats.

Integrative oncology focuses on making the body less “hospitable” to cancer while enhancing the effectiveness of new treatments.

Key strategies include:

  • Metabolic and mitochondrial nutrition: Following a nutrient-dense, low-carbohydrate, anti-inflammatory diet rich in  healthy fats like olive oil and wild fish, phytonutrients from non-starchy plants and clean proteins can help starve cancer cells of glucose while fueling healthy mitochondria.
  • Phytonutrients and targeted supplements: Compounds such as curcumin, resveratrol, grape seed extract, and berberine support immune balance and reduce tumor-promoting inflammation.
  • Oxygenation and detoxification: Improving oxygen delivery through oxygenation therapies like EWOT and hyperbaric,  breathwork and exercise can reduce hypoxia, a driver of angiogenesis and tumor aggressiveness.
  • Vitamin D and K2 optimization: Active vitamin D and K supports immune function and healthy cell differentiation as well as helping to regulate calcium and protect bone tissue.
  • Cruciferous vegetables and medicinal mushrooms: Broccoli sprouts, kale, and shiitake mushrooms contain natural compounds that help neutralize carcinogens and support detoxification enzymes.

These terrain-focused strategies create conditions where cancer has less opportunity to seed, grow, or metastasize, and where innovative therapies like MBTA and SYNC-T can work even better.

A Holistic Vision for the Future

We are entering a new era of cancer care, one that values precision, immunity, and healing over indiscriminate destruction.
The emerging science of intratumoral immunotherapy shows that we can activate the body’s own intelligence to identify and destroy cancer cells. At the same time, integrative metabolic care strengthens the body’s resilience, restores balance, and reduces the risk of recurrence.

Systemic chemotherapy may still have a role in certain cancers, but it should no longer be the default or only path. Patients deserve options that heal, not harm, treatments that extend life while preserving vitality, immunity, and hope.

The Takeaway

Intratumoral therapies like MBTA and SYNC-T represent a promising shift away from the era of blanket chemotherapy. When paired with an integrative, terrain-supportive approach, nutritional, metabolic, and immune-restorative, we finally begin to treat both the seed and the soil of cancer.

The future of oncology is not just about killing cancer. It’s about restoring balance, awakening immunity, and reclaiming health.

How Oxygen Fights Cancer: The Role of EWOT in Tumor Health and Immune Support - Exercising on bikes

How Oxygen Fights Cancer: The Role of EWOT in Tumor Health and Immune Support

, 0

How Oxygen Fights Cancer: The Role of EWOT in Tumor Health and Immune Support

How Oxygen Fights Cancer: The Role of EWOT in Tumor Health and Immune Support

Cancer isn’t just a cluster of rogue cells, it’s a dynamic and evolving environment. Within that environment, oxygen plays a powerful and often underestimated role. Emerging research suggests that therapies that boost oxygen levels, such as Exercise With Oxygen Therapy (EWOT), may help to weaken tumors and strengthen the body’s own defense systems.

In this article, we’ll explore how oxygen affects the tumor microenvironment, how it lowers harmful factors like VEGF and HIF-1, and why increasing oxygen through EWOT could be a supportive tool in cancer care.

Understanding the Tumor Microenvironment

Cancer cells don’t grow in isolation. They interact with and manipulate their surroundings—blood vessels, immune cells, connective tissue, and signaling molecules—to create a supportive habitat called the tumor microenvironment (TME).

One of the defining characteristics of the TME is hypoxia—a lack of oxygen. As tumors grow rapidly, they often outpace their blood supply, leaving areas within the tumor starved for oxygen. This low-oxygen environment isn’t just a side effect; it actually helps tumors thrive.

Why Hypoxia Fuels Cancer

When oxygen levels drop, cancer cells activate survival mechanisms. Two of the most important players in this hypoxic response are:

1. HIF-1 (Hypoxia-Inducible Factor 1)

HIF-1 is a transcription factor that becomes stabilized in low oxygen conditions. Once active, HIF-1 turns on genes that help cancer cells survive and spread, including those that:

  • Promote angiogenesis (new blood vessel growth)
  • Increase glucose metabolism (a hallmark of cancer)
  • Suppress immune detection

2. VEGF (Vascular Endothelial Growth Factor)

HIF-1 directly stimulates VEGF, a key driver of blood vessel formation. While new vessels might sound good, tumor blood vessels are often leaky and disorganized, worsening hypoxia and making it harder for chemotherapy or immune cells to reach the tumor.

In short: hypoxia → HIF-1 activation → VEGF upregulation → chaotic tumor growth and immune evasion.

How Oxygen Can Turn the Tables

By increasing oxygen availability in the tumor microenvironment, we can disrupt this vicious cycle.

Oxygen downregulates HIF-1

Oxygen is a natural suppressor of HIF-1. In well-oxygenated conditions, HIF-1 is rapidly degraded and cannot trigger the cascade of genes that protect the tumor.

Oxygen reduces VEGF expression

With lower HIF-1 activity, the production of VEGF also drops. This can help “normalize” the tumor vasculature, improving blood flow, reducing metastasis, and enhancing the delivery of therapies.

Oxygen supports the immune response

Immune cells, especially cytotoxic T-cells and natural killer (NK) cells, require oxygen to function optimally. In a hypoxic environment, their ability to recognize and destroy cancer cells is impaired. Oxygen-rich conditions help restore immune surveillance and anti-tumor activity.

What is EWOT? (Exercise With Oxygen Therapy)

EWOT combines moderate exercise (usually on a bike or treadmill) with the inhalation of high-concentration oxygen, typically delivered through a mask hooked up to an oxygen concentrator or reservoir.

The combination of movement and high flow rate oxygen consumption creates a synergistic effect:

  • Exercise increases heart rate and blood flow
  • Oxygen is more effectively delivered to tissues, including poorly perfused areas
  • Over time, EWOT may improve microcirculation and oxygen utilization at the cellular level

This method has been used for decades in sports performance and chronic disease management, but it’s now gaining attention in integrative oncology settings.

Potential Benefits of EWOT in Cancer Care

While EWOT is not a standalone treatment for cancer, it may offer adjunctive support by:

  • Improving tissue oxygenation, especially in areas with poor blood supply
  • Lowering HIF-1 and VEGF expression, disrupting tumor growth signals
  • Enhancing immune function, helping the body mount a stronger anti-cancer response
  • Boosting mitochondrial function, which may improve energy metabolism and recovery
  • Enhancing effectiveness of therapies, such as radiation and some forms of chemotherapy, which depend on oxygen for maximum efficacy

A Word of Caution

While the science behind oxygen and cancer is compelling, it’s important to note that not all cancers behave the same way, and oxygen therapy is not a cure. Anyone considering EWOT should do so under the guidance of a qualified healthcare provider—preferably one with experience in integrative oncology.

Conclusion: Oxygen as an Ally

The idea that something as simple as oxygen could weaken cancer may seem surprising, but the research is catching up to what many clinicians are already seeing in practice. By targeting the hypoxic tumor microenvironment, therapies like EWOT may help tip the balance in favor of healing.

In the battle against cancer, oxygen isn’t just a passive participant, it’s a powerful ally.

Further Reading / Sources

  • Semenza, G.L. (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in Pharmacological Sciences.
  • Vaupel, P. & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews.
  • Allen, J. et al. (2018). The role of oxygen in cancer therapy: strategies to overcome hypoxia. Nature Reviews Cancer.

Mistletoe in Cancer Care

Mistletoe in Cancer Care: What Johns Hopkins Found and Why It Matters

0

Mistletoe in Cancer Care: What Johns Hopkins Found and Why It Matters

Mistletoe in Cancer Care: What Johns Hopkins Found and Why It Matters

When you hear the word mistletoe, chances are you think of the holidays, green sprigs hanging in doorways, warm gatherings, maybe even a kiss. But there’s another side to this humble plant that’s been quietly making waves in the medical world. Researchers are now exploring mistletoe not as a festive decoration, but as a potential partner in cancer care.

At Johns Hopkins, a team of oncologists recently conducted the first U.S. clinical trial on mistletoe extract for patients with advanced cancer. Around the same time, the book Mistletoe and the Emerging Future of Integrative Oncology was published, sharing stories and insights about how this plant is already being used in integrative medicine around the world.

Together, the study and the book tell a story of ancient wisdom meeting modern science, and of new hope for patients looking for more holistic options in their care.

The Johns Hopkins Trial: A First Step in the U.S.

In 2023, the Johns Hopkins Kimmel Cancer Center tested an intravenous form of mistletoe extract called Helixor M in patients with advanced, treatment-resistant cancers.

The trial was small, but the findings were encouraging:

  • Safety came first. Mistletoe was given through an IV three times a week. Even at higher doses, side effects were generally mild, things like fatigue, chills, or nausea.
  • Some patients stabilized. A number of participants had their cancer remain stable for several weeks to months, and a few even saw their tumors shrink temporarily.
  • Quality of life improved. Perhaps most striking, patients reported feeling better overall, more energy, improved mood, and a stronger sense of well-being.

For doctors, this matters. It shows that mistletoe can be safely studied in the U.S., and that it may not only affect cancer itself, but also how people feel during treatment. That’s a big deal in oncology, where side effects and exhaustion can take such a toll.

Beyond the Data: A Book of Stories and Perspective

While the Johns Hopkins trial focused on clinical safety and outcomes, the book Mistletoe and the Emerging Future of Integrative Oncology brings the human side into the picture.

Written by integrative oncologists and practitioners, the book explores mistletoe therapy as part of a larger movement to blend conventional cancer treatment with holistic approaches. In Europe, mistletoe has been used for decades alongside chemotherapy and radiation, not as a replacement, but as a complement.

Some of the key messages from the book include:

  • Healing is more than fighting disease. It’s also about restoring vitality, easing side effects, and helping patients feel like themselves again.
  • Bridging two worlds. Mistletoe symbolizes a bridge between modern science and natural medicine, offering patients the best of both.
  • Personalized care matters. No two people are the same, and mistletoe therapy can be adapted to the individual, something patients often long for in their treatment journey.

The tone is hopeful, human, and deeply patient-centered.

Why Mistletoe Could Be a Game-Changer

Cancer care is often laser-focused on the tumor. But patients know their journey is about so much more, their energy, resilience, emotions, and quality of life. That’s where therapies like mistletoe could shine.

  • It may support the immune system, helping the body cope with both cancer and conventional treatments.
  • It has shown potential to reduce side effects and improve well-being.
  • It represents a philosophy of care that honors the whole person, not just the disease.

We’re still at the beginning of this journey in the U.S., and mistletoe isn’t a stand-alone cure. But when science and holistic wisdom meet, the result is often a more compassionate, balanced approach to healing.

A Closing Reflection

It feels almost poetic: the same plant we hang in doorways to bring people together might also help bring two sides of medicine together, conventional oncology and integrative healing.

Mistletoe may be rooted in ancient tradition, but its role in modern cancer care is just beginning to blossom.

For patients and families searching for options that care for both body and spirit, this little green plant could hold surprising promise.

If you’re interested in learning more about mistletoe therapy and integrative cancer care, resources like Johns Hopkins Kimmel Cancer Center and the book Mistletoe and the Emerging Future of Integrative Oncology are wonderful places to start.

High-Dose IV Vitamin C and Cancer: What You Need to Know

High-Dose IV Vitamin C and Cancer: What You Need to Know

, 0

High-Dose IV Vitamin C and Cancer:
What You Need to Know

High-Dose IV Vitamin C and Cancer: What You Need to Know

High-dose intravenous vitamin C (IVC), typically 50 grams or more per infusion. is being studied worldwide as a promising adjunct, or integrative treatment, to conventional cancer care. At these higher doses, vitamin C acts very differently than when taken orally, and research suggests it may help shrink tumors, improve outcomes, and reduce treatment side effects.

How It Works

When given intravenously, vitamin C bypasses tight gut absorption controls and reaches blood levels 100–500 times higher than oral dosing NCI PDQ, 2024. At these concentrations, vitamin C can act as a pro-oxidant in tumors, generating hydrogen peroxide (H₂O₂). Cancer cells, often deficient in detox enzymes, are more vulnerable to this oxidative stress, while healthy cells neutralize it effectively Chen et al., PNAS 2008.

Clinical Evidence So Far

  • Ovarian cancer: In a small randomized study, adding high-dose IVC to carboplatin and paclitaxel reduced chemotherapy-related toxicity and showed signs of improved effectiveness Ma et al., Sci Transl Med 2014.
  • Pancreatic cancer: A phase 2 randomized trial found patients receiving IVC (75 g, three times weekly) alongside gemcitabine and nab-paclitaxel lived significantly longer than those on chemotherapy alone Bodeker et al., Redox Biology 2024.
  • Glioblastoma (brain cancer): In a phase I trial, IVC combined safely with radiation and temozolomide and showed encouraging survival signals Allen et al., Clin Cancer Res 2019.

These results are early but consistent: IVC is safe when monitored correctly and may improve both quality of life and survival when paired with standard treatments.

Safety and Screening

High-dose IVC is well-tolerated when patients are properly screened. Important precautions include:

  • G6PD testing: to rule out deficiency and prevent hemolysis NCI PDQ, 2024.
  • Kidney function check
  • Glucose monitoring caution: high-dose IVC can cause false high readings on fingerstick glucose meters UCSF Lab Advisory, 2019.

Synergy With Conventional Care

What excites researchers most is IVC’s synergy with standard therapies:

  • Enhancing chemotherapy effects while reducing side effects (ovarian, pancreatic).
  • Acting as a radiosensitizer, making tumors more sensitive to radiation, while protecting normal tissue Doskey et al., Cancer Res 2018.
  • Potentially supporting immune responses, with early lab data suggesting improved activity of checkpoint inhibitors.

Key Takeaway

High-dose IV vitamin C is not a cure by itself. But research, including randomized trials, is showing that when used integratively, it improves survival and reduce side effects for some cancers. With proper medical supervision and safety screening, IVC represents an exciting integrative option for patients seeking to strengthen outcomes and resilience during treatment.

References

  1. National Cancer Institute. PDQ® Vitamin C (Intravenous) – Health Professional Version.
  2. Ma Y, et al. Sci Transl Med. 2014;6(222):222ra18.
  3. Bodeker K, et al. Redox Biol. 2024;65:102299.
  4. Allen BG, et al. Clin Cancer Res. 2019;25(23):7416–7428.
  5. Chen Q, et al. PNAS. 2008;105(32):11105–11109.
  6. Doskey CM, et al. Cancer Res. 2018;78(24):6838–6848.

Load More